SSRI/SNRI Pregnancy Exposure Risks Should Be In Patient Labeling, Pediatric Subcmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Subcommittee rejects public health advisory on selective serotonin re-uptake inhibitor withdrawal syndrome risks to newborns. FDA is preparing class labeling that will add precautions to pregnancy section of SSRI/SNRIs.
You may also be interested in...
Paxil CR "Dear Doctor" Letter Reflects New Labeling On Birth Defects
Preliminary results from a retrospective epidemiologic study suggest an increased risk of congenital malformations associated with the use of paroxetine by pregnant women over other antidepressants, the letter states.
Paxil CR "Dear Doctor" Letter Reflects New Labeling On Birth Defects
Preliminary results from a retrospective epidemiologic study suggest an increased risk of congenital malformations associated with the use of paroxetine by pregnant women over other antidepressants, the letter states.
FDA Forms Pediatric Ethics Subcommittee
The advisory panel will address pediatric ethical issues and IRB referrals related to clinical investigations involving children. The subcommittee's preliminary recommendations will be presented to the new Pediatric Advisory Committee.